预测高反应者的辅助生殖技术临床结局:卵母细胞体外成熟与传统卵巢刺激用于体外受精/卵胞浆内单精子注射的比较
本回顾性队列研究纳入2016年1月至2022年6月间1707个周期,比较预测高反应者(血清抗苗勒管激素≥3.25 ng/ml)接受卵母细胞体外成熟(IVM)或传统卵巢刺激(OS)后的持续妊娠率。在血清抗苗勒管激素≥10 ng/ml的女性中,单周期IVM的持续妊娠率非劣效于OS。
要点
- 预测高反应者中,IVM组与OS组未调整持续妊娠率分别为42.8%与63.8%。
- 血清抗苗勒管激素>10 ng/ml时,IVM组持续妊娠率为51.1%,OS组为60.4%,IVM非劣效于OS。
- 两组达到持续妊娠所需的胚胎移植次数相当(1.6次 vs 1.5次,P=0.44)。
核心结论
- 在血清抗苗勒管激素≥10 ng/ml的预测高反应者中,单周期IVM的持续妊娠率非劣效于单周期OS。
研究设计与样本
- 回顾性队列分析,纳入2016年1月至2022年6月间某三级转诊大学医院的1707个周期(IVM组463个,OS组1244个)。
- 研究对象为≤36岁的预测高反应者(血清抗苗勒管激素≥3.25 ng/ml),接受高度纯化尿促性素(HP-hMG)预处理的非hCG触发IVM或传统OS(GnRH拮抗剂方案中FSH或HP-hMG刺激)后行ICSI。
- 主要结局为胚胎移植后10-11周评估的累积持续妊娠率,预设非劣效界值为-10.0%。
主要发现
- IVM组较OS组更多诊断为鹿特丹PCOS(434/463,93.7% vs 522/1193,43.8%),更年轻(29.5岁 vs 30.5岁,P≤0.001),BMI更高(25.7 kg/m2 vs 25.1 kg/m2,P≤0.01),抗苗勒管激素更高(11.6 ng/ml vs 5.3 ng/ml,P≤0.001)。
- IVM组获卵丘卵母细胞复合物数更多(24.5 vs 15.0,P≤0.001),但两组成熟卵母细胞(MII)数相似(11.9 vs 10.6,P=0.9)。
- 全队列未调整累积持续妊娠率IVM组显著低于OS组(198/463,42.8% vs 794/1244,63.8%,P≤0.001)。
- 随血清抗苗勒管激素升高,两组累积持续妊娠率趋同;血清抗苗勒管激素>10 ng/ml时,IVM组持续妊娠率为51.1%(113/221),OS组为60.4%(29/48),IVM非劣效于OS。
- 两组达到持续妊娠所需胚胎移植次数相当(IVM组1.6次 vs OS组1.5次,P=0.44)。
局限性
- 研究为回顾性性质,存在未测量混杂因素的可能性,数据应谨慎解读。
- 作者指出这些发现应通过在选定抗苗勒管激素升高患者中比较两种治疗的随机对照试验(RCT)加以证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Do ongoing pregnancy rates (OPRs) differ in predicted hyperresponders undergoing ART after IVM of oocytes compared with conventional ovarian stimulation (OS) for IVF/ICSI? SUMMARY ANSWER: One cycle of IVM is non-inferior to one cycle of OS in women with serum anti-Müllerian hormone (AMH) levels ≥10 ng/ml. WHAT IS KNOWN ALREADY: Women with high antral follicle count and elevated serum AMH levels, indicating an increased functional ovarian reserve, are prone to hyperresponse during ART treatment. To avoid iatrogenic complications of OS, IVM has been proposed as a mild-approach alternative treatment in predicted hyperresponders, including women with polycystic ovary syndrome (PCOS) who are eligible for ART. To date, inferior pregnancy rates from IVM compared to OS have hampered the uptake of IVM by ART clinics. However, it is unclear whether the efficiency gap between IVM and OS may differ depending on the extent of AMH elevation. STUDY DESIGN, SIZE, DURATION: This study is a retrospective cohort analysis of clinical and laboratory data from the first completed highly purified hMG (HP-hMG) primed, non-hCG-triggered IVM or OS (FSH or HP-hMG stimulation in a GnRH antagonist protocol) cycle with ICSI in predicted hyperresponders ≤36 years of age at a tertiary referral university hospital. A total of 1707 cycles were included between January 2016 and June 2022. PARTICIPANTS/MATERIALS, SETTING, METHODS: Predicted hyperresponse was defined as a serum AMH level ≥3.25 ng/ml (Elecsys® AMH, Roche Diagnostics). The primary outcome was cumulative ongoing pregnancy rate assessed 10-11 weeks after embryo transfer (ET). The predefined non-inferiority limit was -10.0%. The analysis was adjusted for AMH strata. Time-to-pregnancy, defined as the number of ET cycles until ongoing pregnancy was achieved, was a secondary outcome. Statistical analysis was performed using a multivariable regression model controlling for potential confounders. MAIN RESULTS AND THE ROLE OF CHANCE: Data from 463 IVM cycles were compared with those from 1244 OS cycles. Women in the IVM group more often had a diagnosis of Rotterdam PCOS (434/463, 93.7%) compared to those undergoing OS (522/1193, 43.8%), were significantly younger (29.5 years versus 30.5 years, P ≤ 0.001), had a higher BMI (25.7 kg/m2 versus 25.1 kg/m2, P ≤ 0.01) and higher AMH (11.6 ng/ml versus 5.3 ng/ml, P ≤ 0.001). Although IVM cycles yielded more cumulus-oocyte complexes (COCs) (24.5 versus 15.0 COC, P ≤ 0.001), both groups had similar numbers of mature oocytes (metaphase II (MII)) (11.9 MII versus 10.6 MII, P = 0.9). In the entire cohort, non-adjusted cumulative OPR from IVM was significantly lower (198/463, 42.8%) compared to OS (794/1244, 63.8%), P ≤ 0.001. When analysing OPR across different serum AMH strata, cumulative OPR in both groups converged with increasing serum AMH, and OPR from IVM was non-inferior compared to OS from serum AMH levels >10 ng/ml onwards (113/221, 51.1% (IVM); 29/48, 60.4% (OS)). The number of ETs needed to reach an ongoing pregnancy was comparable in both the IVM and the OS group (1.6 versus 1.5 ET's, P = 0.44). Multivariable regression analysis adjusting for ART type, age, BMI, oocyte number, and PCOS phenotype showed that the number of COCs was the only parameter associated with OPR in predicted hyperresponders with a serum AMH >10 ng/ml. LIMITATIONS, REASONS FOR CAUTION: These data should be interpreted with caution as the retrospective nature of the study holds the possibility of unmeasured confounding factors. WIDER IMPLICATIONS OF THE FINDINGS: Among subfertile women who are eligible for ART, IVM, and OS resulted in comparable reproductive outcomes in a subset of women with a serum AMH ≥10 ng/ml. These findings should be corroborated by a randomised controlled trial (RCT) comparing both treatments in selected patients with elevated AMH. STUDY FUNDING/COMPETING INTEREST(S): There was no external funding for this study. P.D. has been consultant to Merck Healthcare KGaA (Darmstadt, Germany) from April 2021 till June 2023 and is a Merck employee (Medical Director, Global Medical Affairs Fertility) with Merck Healthcare KGAaA (Darmstadt, Germany) since July 2023. He declares honoraria for lecturing from Merck KGaA, MSD, Organon, and Ferring. The remaining authors declared no conflict of interest pertaining to this study. TRIAL REGISTRATION NUMBER: N/A.
引用
- Mostinckx L, Goyens E, Mackens S, et al. Clinical outcomes from ART in predicted hyperresponders: in vitro maturation of oocytes versus conventional ovarian stimulation for IVF/ICSI. Hum Reprod. 2024. PMID: 38177084. doi:10.1093/humrep/dead273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。